The drugmaker began the strategic review of its businesses in early 2017 and noted the possibility of splitting off units, making acquisitions, selling assets or using capital to buy back shares.
The decision to sell off the units comes as the drugmaker looks to shore up finances after a difficult year, in which its shares fell 32 percent.
The women’s health unit is valued at $4 billion, and the infectious disease business is valued at $2 billion.
More articles on supply chain:
90% of ER physicians had shortages of critical medicine in the last month: 5 notes
Red Cross offers blood donors $5 Amazon gift card to boost summer donations
FDA greenlights test to detect sepsis-causing bacteria in blood
